New study aims to crack the code of kidney cancer treatment response
NCT ID NCT05782400
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is looking for clues in blood, tumor tissue, and CT scans to help doctors choose the best first treatment for people with metastatic clear cell kidney cancer. Researchers will analyze genetic material and imaging features from 100 patients to see if they can predict who will respond well to different therapies. The goal is to move toward personalized treatment, but this is an early step to find promising patterns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a way to predict which treatment works best for each person with metastatic kidney cancer, making therapy more personalized.
- What could go wrong
- This is an early exploratory study with only 100 participants. It aims to find patterns, not test a treatment, so it may not directly change care. Results need validation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istituto Tumori
Milan, Mi, 20156, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.